20 domestically-made innovative drugs may undergo initial medical insurance negotiations to accelerate drug volume

 After the entry of innovative drugs into the medical insurance, it is expected to improve the problem of difficult access and achieve rapid penetration of coverage in hospitals and pharmacies.
Therefore, more and more domestic innovative drugs are accelerating the advancement of the medical insurance catalog
.
It is understood that the 2021 national medical insurance negotiations will begin on November 9, and data show that there are about 20 domestically-made innovative drug varieties this time or the initial negotiation will be held
.
The 2021 national medical insurance negotiations will start on November 9th and end on November 11th.
The negotiation will last for 3 days
.
According to relevant agencies, it is estimated that about 20 domestically-made innovative drug varieties will be negotiated for the first time this year
.
In terms of disease fields, 12 of these 20 varieties are innovative anti-tumor drugs, of which 3 are targeted at hematoma; the other 4 are anti-infective drugs, drugs for metabolic diseases, drugs for autoimmune diseases, and drugs for hematological diseases.
, 1 anesthetic each
.
It is understood that it will include PARP inhibitors, BTK inhibitors, ALK inhibitors, ADC drugs (antibody-coupled drugs), CAR-T therapy (chimeric antigen receptor T cell immunotherapy), etc.
, involving Betta Pharmaceuticals, Many listed pharmaceutical companies such as BeiGene, Hengrui Pharmaceuticals, and Zejing Pharmaceuticals
.
According to the industry, the anti-tumor drug PD-1 monoclonal antibody is still the focus of medical insurance negotiations, but among domestic products, the companies and varieties that are eligible to participate in the medical insurance negotiations in 2021 are the 4 varieties that participated in the medical insurance negotiations last year, and the competitive landscape is still relatively relaxed
.
It is understood that the current domestic PD-1 market is fiercely competitive.
There are 10 PD-1/L1 approved for listing, new indications are continuously approved, and the listing of new drugs continues to accelerate.
The industry predicts that by 2022, the PD- The competition faced by 1/L1 monoclonal antibody may be more intense
.
Innovative drugs are expected to improve access difficulties after entering the medical insurance.
For example, in terms of entering the hospital drug list, the entry of drugs into the medical insurance is expected to reduce the admission threshold and accelerate the efficiency of hospital admission; in terms of entering the pharmacy, the drugs are expected to be negotiated through the national medical insurance after entering the medical insurance The “dual-channel” management mechanism accelerates the entry of pharmacies to achieve high volume
.
In addition, in May this year, the National Medical Insurance Administration and the National Health Commission issued the "Guiding Opinions on Establishing and Improving the "Dual Channel" Management Mechanism for Drugs in National Medical Insurance Negotiations".
After the drugs entered the medical insurance catalogue, it is expected to accelerate the pharmacy through the "dual channel" mechanism.
High-end products
.
According to the industry, medical insurance negotiations have become an important catalyst for innovative drug companies to increase the volume of their products
.
For example, from the experience of the previous rounds of medical insurance negotiations, most innovative drugs have achieved substantial growth in the amount of money after entering the medical insurance through price-for-volume exchange
.
According to relevant data, among the 34 innovative drugs on the market from 2016 to 2020, 26 drugs have entered the medical insurance catalog, accounting for 76.
5%
.
The time for innovative drugs to be included in medical insurance has also been greatly shortened.
In 2017, it will take 4 to 9 years for new drugs to enter medical insurance.
It will be shortened to 1 to 8 years in 2019, and it will be further compressed to 0.
5 to 5 years in 2020.
Years
.
It is understood that in recent years, the domestic innovative drug industry has developed vigorously.
However, due to the complex competitive landscape in the industry, it has become the unanimous choice of domestic pharmaceutical companies to accelerate drug volume with the help of medical insurance
.
According to the industry, in this context, in order to maintain the existing first-mover advantage, innovative drugs that are first approved for listing generally choose to enter the medical insurance catalog at a price-for-volume basis soon after the listing; then the innovative drugs that are approved for listing are to seize market share.
, Also actively participates in medical insurance negotiations, with the intention of expanding market share through medical insurance
.